FOR IMMEDIATE RELEASE
BioStratum Reports Drug Candidate Pyridorin™ Demonstrates Improved
Performance in Preventing Kidney Disease in Animal Models of Diabetes
Research Triangle Park, N.C. -- October 29, 1998 -- BioStratum Incorporated
today announced the presentation of preclinical results demonstrating
the effectiveness of its drug candidate Pyridorin™ in preventing the development
Collaborating scientists from the University of South Carolina led by
Dr. John Baynes presented promising preclinical results from Pyridorin™
experiments which employed the streptozotocin (STZ) diabetic animal model.
In addition, collaborating scientists from the University
In diabetes, elevated levels of glucose are known to promote the non-enzymatic
glycation of proteins, which
The formation of AGEs can proceed through a number
This advancement provided for a novel in vitro screening method to search
for novel post-Amadori inhibitors of AGE formation. Initial screening
studies on known inhibitors of AGE formation, including aminoguanidine,
showed little post-Amadori inhibitory activity. Subsequent screening studies
led to the identification of Pyridorin as a unique and potent inhibitor
of the conversion of post-Amadori protein intermediates to AGEs. These
advances led BioStratum
These studies also monitored changes in plasma levels
BioStratum collaborators from the University of Kansas reported Pyridorin
to be highly effective at preventing
These results suggest that the specific inhibition of the conversion of protein Amadori intermediates to AGEs is a therapeutically relevant in vivo target, and that drugs which target this conversion may be more effective at inhibiting the development of diabetic kidney disease than drugs that target other mechanisms of AGE formation.
Dr. Archie Prestayko, BioStratum's President and CEO commented, "We believe Pyridorin's unique mechanism of action could be an important advancement to the current management of patients with diabetic nephropathy. We are now conducting IND enabling toxicity studies, and look forward to our Phase I clinical trails that are expected to begin during the second quarter of 1999."
In the U.S. approximately 30 to 40 percent of insulin dependent Type I diabetics and 10-15% of non-insulin dependent Type II diabetics (a total of 1.5 million patients) develop nephropathy, which is the leading cause of end-stage renal failure.
BioStratum is a privately held company developing proprietary therapeutics based on recent scientific advances in basal lamina and related technologies. The company's drug candidates are directed against novel basal lamina extracellular targets involved in degenerative and invasive disease processes fundamental to kidney disease, diabetes and cancer. The company has also developed methods for the production of recombinant basal lamina proteins for use in wound repair and advanced tissue regeneration protocols.